美诺加 ril 治疗子宫颈鳞状细胞癌患者的 II 期试验：一项妇科肿瘤学组研究。

Phase II trial of menogaril in patients with squamous carcinoma of the cervix: a Gynecologic Oncology Group study.

作者信息

Sutton G P, Blessing J A, Barrett R J, Gallup D G

机构信息

Section of Gynecologic Oncology, Indiana University Medical School, Indianapolis.

出版信息

Gynecol Oncol. 1994 Feb;52(2):229-31. doi: 10.1006/gyno.1994.1036.

DOI:10.1006/gyno.1994.1036

PMID:8314144

Abstract

A phase II trial of 200 mg/m2 menogaril was conducted by the Gynecologic Oncology Group (GOG) in women with advanced or recurrent squamous carcinoma of the cervix who had received no previous chemotherapy. Twenty-three patients were placed on the study; 22 are evaluable for toxicity and for response. One patient had incomplete data and was inevaluable. Nine patients (40.9%) had previously undergone surgery, and 21 (95.5%) had received radiotherapy before this trial. GOG grade 3 granulocytopenia occurred in 1 patient (4.5%) but none developed grade 3 or 4 thrombocytopenia. One patient (4.5%) had grade 3 gastrointestinal toxicity. Neither complete nor partial responses were observed in this trial, although 9 patients (40.9%) had stable disease lasting 2 months or more. Menogaril at this dose and schedule is inactive in advanced or recurrent squamous carcinoma of the cervix.

摘要

妇科肿瘤学组（GOG）对未接受过化疗的晚期或复发性子宫颈鳞状癌女性患者进行了一项甲吲噻腙剂量为200 mg/m²的II期试验。23名患者参与了该研究；22名患者可进行毒性和疗效评估。1名患者数据不完整，无法评估。9名患者（40.9%）此前接受过手术，21名患者（95.5%）在本次试验前接受过放疗。1名患者（4.5%）出现了GOG 3级粒细胞减少，但无人出现3级或4级血小板减少。1名患者（4.5%）出现了3级胃肠道毒性。尽管9名患者（40.9%）病情稳定持续2个月或更长时间，但本次试验中未观察到完全缓解或部分缓解。该剂量和给药方案的甲吲噻腙对晚期或复发性子宫颈鳞状癌无效。